Company / Cost of Revenue
Vir Biotechnology, Inc. Cost of Revenue History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$26.0K
FY2025
5-year range
$0 / $2.8M
FY2021-FY2025
Trend
-96.9%
vs FY2024
Sector context
#82 of 85
Health Care
What the data says
Among 85 Health Care companies, Vir Biotechnology, Inc. is in the top 4% for cost of revenue. Improved from $3M to $26,000 over the past 2 years.
Based on SEC 10-K filings.
$26,000 in FY2025.
Improved from $3M to $26,000 over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 85This company $26.0K Sector average $2.0B
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2025, cost of revenue decreased 96.9% year-over-year.
- Ranks #82 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
- Lowest cost of revenue in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.0K | -96.9% |
| FY2024 | $845.0K | -69.4% |
| FY2023 | $2.8M | - |
| FY2022 | $0 | - |
| FY2021 | $0 | - |
| FY2020 | $0 | - |
| FY2019 | $0 | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026